CDK1 and prostate carcinoma: In summary, these results showed that deregulation of the cell cycle by inhibition of the activity of the upstream signaling molecules Cdk1 and Cdk2 is at least partly involved in NED modulation in AR-positive prostate cancer cell lines LNCaP and LAPC-4.